文献速递慢性肾脏病

非透析慢性肾脏病患者中促红细胞生成素刺激剂类型与终末期肾病及死亡风险

Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本研究基于四项观察性研究的汇总队列,纳入接受短效或长效促红细胞生成素刺激剂(ESA)治疗的非透析慢性肾脏病(CKD)患者,比较两类ESA使用者发生终末期肾病(ESKD)或全因死亡复合终点的风险。结果显示,在高剂量短效ESA组中,主要终点风险显著高于低剂量组,且在高剂量三分位中短效ESA风险显著高于长效ESA;较高剂量下短效ESA可能与ESKD或死亡风险增加相关。

要点

  • 高剂量短效ESA与ESKD或死亡风险增加相关,剂量越高风险越高
  • 高剂量三分位中短效ESA风险显著高于长效ESA(HR 1.56)
  • 剂量>105 IU/kg/周时短效与长效ESA风险差异显著

核心结论

  • 在非透析CKD患者中,高剂量短效ESA可能与ESKD或死亡风险增加相关,而长效ESA未显示剂量依赖风险。

研究设计与样本

  • 汇总四项观察性研究的队列,纳入接受短效ESA(n=299)或长效ESA(n=403)的非透析CKD患者。
  • 采用多变量Cox模型估计主要复合终点(ESKD或全因死亡)的相对风险。

主要发现

  • 中位随访3.6年(IQR 2.1-6.3),主要终点在短效ESA组发生166例(72%),长效ESA组235例(58%)。
  • 短效ESA最高剂量三分位相比最低三分位,主要终点调整风险HR 2.07(95%CI 1.37-3.12)。
  • 长效ESA各剂量三分位间主要终点风险无显著变化。
  • 最高剂量三分位中,短效ESA相比长效ESA的主要终点风险HR 1.56(95%CI 1.09-2.24;P=0.016)。
  • 将ESA剂量作为连续变量分析,剂量>105 IU/kg/周时短效与长效ESA的主要终点差异显著。

临床怎么用

  • 对非透析CKD贫血患者使用短效ESA时,应关注较高剂量可能带来的ESKD或死亡风险增加。
  • 在需要较高ESA剂量时,可考虑长效ESA作为替代选择,但需结合个体情况评估。

局限性

  • 研究为观察性设计,可能存在残留混杂,无法确立因果关系。
  • 样本来自四项研究的汇总,短效与长效ESA组样本量不均衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the widespread use of erythropoiesis-stimulating agents (ESAs) to treat anaemia, the risk of adverse outcomes associated with the use of different types of ESAs in non-dialysis chronic kidney disease (CKD) is poorly investigated. METHODS: From a pooled cohort of four observational studies, we selected CKD patients receiving short-acting (epoetin α/β; n = 299) or long-acting ESAs (darbepoetin and methoxy polyethylene glycol-epoetin β; n = 403). The primary composite endpoint was end-stage kidney disease (ESKD; dialysis or transplantation) or all-cause death. Multivariable Cox models were used to estimate the relative risk of the primary endpoint between short- and long-acting ESA users. RESULTS: During follow-up [median 3.6 years (interquartile range 2.1-6.3)], the primary endpoint was registered in 401 patients [166 (72%) in the short-acting ESA group and 235 (58%) in the long-acting ESA group]. In the highest tertile of short-acting ESA dose, the adjusted risk of primary endpoint was 2-fold higher {hazard ratio [HR] 2.07 [95% confidence interval (CI) 1.37-3.12]} than in the lowest tertile, whereas it did not change across tertiles of dose for long-acting ESA patients. Furthermore, the comparison of ESA type in each tertile of ESA dose disclosed a significant difference only in the highest tertile, where the risk of the primary endpoint was significantly higher in patients receiving short-acting ESAs [HR 1.56 (95% CI 1.09-2.24); P = 0.016]. Results were confirmed when ESA dose was analysed as continuous variable with a significant difference in the primary endpoint between short- and long-acting ESAs for doses >105 IU/kg/week. CONCLUSIONS: Among non-dialysis CKD patients, the use of a short-acting ESA may be associated with an increased risk of ESKD or death versus long-acting ESAs when higher ESA doses are prescribed.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Minutolo R, Garofalo C, Chiodini P, et al. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant. 2021. PMID: 32829405. doi:10.1093/ndt/gfaa088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。